David P Kelsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/545287/publications.pdf

Version: 2024-02-01

82 papers	6,355 citations	94269 37 h-index	74018 75 g-index
85 all docs	85 docs citations	85 times ranked	7295 citing authors

#	Article	IF	Citations
1	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2022, 89, 255-265.	1.1	1
2	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nature Communications, 2022, 13, 2800.	5.8	21
3	Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Cancer, 2022, 128, 2958-2966.	2.0	2
4	Characterization and Clinical Outcomes of DNA Mismatch Repairâ€“deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	3.2	23
5	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. Journal of the National Cancer Institute, 2021, 113, 1194-1202.	3.0	35
6	Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids. STAR Protocols, 2021, 2, 100225.	0.5	15
7	Conformation-Specific Inhibitory Anti-MMP-7 Monoclonal Antibody Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Chemotherapeutic Cell Kill. Cancers, 2021, 13, 1679.	1.7	4
8	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	2.8	15
9	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	2.0	24
10	Prognostic significance of Tâ€cellâ€“inflamed gene expression profile and PDâ€L1 expression in patients with esophageal cancer. Cancer Medicine, 2021, 10, 8365-8376.	1.3	6
11	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. IScience, 2020, 23, 101844.	1.9	31
12	Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer. Nature Communications, 2020, 11, 6245.	5.8	51
13	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	13.5	691
14	Induction and characterization of pancreatic cancer in a transgenic pig model. PLoS ONE, 2020, 15, e0239391.	1.1	19
15	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 821-831.	5.1	243
16	Reply to N. Fazio. Journal of Clinical Oncology, 2020, 38, 2467-2468.	0.8	1
17	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer, 2020, 126, 3939-3949.	2.0	44
18	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. Journal of Clinical Oncology, 2020, 38, 1378-1388.	0.8	265

#	Article	IF	Citations
19	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research, 2020, 26, 3239-3247.	3.2	135
20	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	3.2	73
21	Pilot study of rapid MR pancreas screening for patients with BRCA mutation. European Radiology, 2019, 29, 3976-3985.	2.3	8
22	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	3.2	10
23	Positron-Emission Tomography Scanâ€"Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. Journal of Thoracic Oncology, 2019, 14, 540-546.	0.5	15
24	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	3.0	170
25	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸F-(2S,4R)-4-Fluoroglutamine. Radiology, 2018, 287, 667-675.	3.6	80
26	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wildâ€type BRCA pancreatic ductal adenocarcinoma. Cancer, 2018, 124, 1374-1382.	2.0	91
27	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	3.2	281
28	The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer, 2018, 21, 1-9.	2.7	41
29	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer, 2018, 89, 19-26.	1.3	125
30	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. British Journal of Cancer, 2017, 116, 697-702.	2.9	70
31	Cancer of the esophagus and esophagogastric junctionâ€"Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 304-317.	157.7	212
32	Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of Gastrointestinal Oncology, 2016, 7, 506-514.	0.6	12
33	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer, 2016, 122, 2083-2090.	2.0	30
34	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology, 2016, 151, 278-287.e6.	0.6	147
35	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-13.	1.4	39
36	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	2.0	167

#	Article	IF	Citations
37	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clinical Colorectal Cancer, 2015, 14, 269-276.e1.	1.0	23
38	Liver-directed conversion therapy in metastatic colon cancer. Journal of Gastrointestinal Oncology, 2015, 6, 322-8.	0.6	1
39	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 319-324.	1.8	83
40	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. Oncologist, 2011, 16, 1397-1402.	1.9	227
41	S-1 adjuvant chemotherapy for advanced gastric cancer. Nature Clinical Practice Oncology, 2008, 5, 370-371.	4.3	0
42	Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer. Journal of Clinical Oncology, 2007, 25, 3719-3725.	0.8	489
43	Multimodality Therapy of Local Regional Esophageal Cancer. Seminars in Oncology, 2005, 32, 6-10.	0.8	11
44	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. , 2002, 9, 954.		3
45	Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma. Journal of Clinical Oncology, 2001, 19, 1985-1992.	0.8	198
46	A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer, 2001, 91, 101-105.	2.0	80
47	Author reply. , 2000, 88, 2426-2426.		1
48	Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemotherapy and Pharmacology, 2000, 45, 389-396.	1.1	55
49	Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer. Journal of Clinical Oncology, 1999, 17, 3270-3275.	0.8	246
50	A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma. Cancer Investigation, 1999, 17, 195-200.	0.6	29
51	Phase II clinical trial of 13-cis-retinoic acid and interferon-?-2a in patients with advanced esophageal carcinoma. , 1999, 85, 1213-1217.		12
52	30 Gy may be an adequate dose in patients with anal cancer treated with excisional biopsy followed by combined-modality therapy. , 1999, 70, 71-77.		45
53	ADJUVANT TREATMENT OF COLORECTAL CANCER. Annual Review of Medicine, 1997, 48, 191-202.	5.0	21
54	9-aminocamptothecin by 72-hour continuous intravenous infusion is Inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. , 1997, 80, 1727-1732.		29

#	Article	IF	Citations
55	Acute toxicity of neoadjuvant bolus 5-FU/methotrexate and leucovorin rescue followed by continuous infusion 5-FU plus pre-operative radiation therapy for rectal cancer. Radiation Oncology Investigations, 1996, 4, 90-97.	1.3	3
56	A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5-fluorouracil + doxorubicin +) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		9
57	A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer, 1995, 75, 2197-2202.	2.0	28
58	The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. International Journal of Cancer, 1995, 64, 37-46.	2.3	86
59	Efficacy of Postoperative 5-FU, High-Dose Leucovorin, and Sequential Radiation Therapy for Clinically Resectable Rectal Cancer. Cancer Investigation, 1995, 13, 1-7.	0.6	16
60	Defining the invasive phenotype of proximal gastric cancer cells. Cancer, 1994, 73, 22-27.	2.0	32
61	Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer, 1994, 73, 5-7.	2.0	25
62	Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. Cancer, 1994, 73, 273-280.	2.0	125
63	A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer, 1994, 74, 958-961.	2.0	64
64	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer, 1994, 74, 2224-2233.	2.0	41
65	A phase I trial of intrahepatic Verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. Cancer, 1994, 74, 2757-2764.	2.0	12
66	The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer, 1993, 71, 3486-3492.	2.0	104
67	A phase II trial of biochemical modulation using N- phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. Cancer, 1992, 70, 1988-1992.	2.0	9
68	A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer, 1991, 68, 965-969.	2.0	79
69	Neoadjuvant chemotherapy and surgery of cancer of the esophagus. Journal of Surgical Oncology, 1990, 6, 268-273.	1.4	35
70	Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract. Investigational New Drugs, 1990, 8, 71-5.	1.2	0
71	Targeted cytogenetic analysis of gastric tumors byin situhybridization with a set of chromosome-specific dna probes. Cancer, 1990, 66, 491-497.	2.0	94
72	A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer, 1990, 66, 659-663.	2.0	72

#	Article	IF	Citations
73	A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies. Cancer, 1990, 66, 1688-1691.	2.0	6
74	Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicity. Cancer, 1990, 66, 2470-2475.	2.0	136
75	Small cell carcinoma of the esophagus. The memorial hospital experience 1970 to 1987. Cancer, 1989, 64, 1531-1533.	2.0	91
76	Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity. Investigational New Drugs, 1988, 6, 239-41.	1.2	8
77	Radiation-induced angiosarcoma. Cancer, 1987, 60, 777-779.	2.0	102
78	Neoadjuvant chemotherapy and surgery of cancer of the esophagus. Journal of Surgical Oncology, 1986, 2, 170-176.	1.4	21
79	Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer, 1985, 55, 527-534.	2.0	217
80	Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy. Cancer, 1985, 56, 2512-2518.	2.0	90
81	Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer. Cancer, 1983, 51, 1050-1055.	2.0	26
82	Pharmacokinetics of gallium nitrate in man. Cancer, 1980, 46, 2009-2013.	2.0	72